Cagrilintide Price Comparison — Compare 24 Vendors

View full research →
GLP-1 / appetite researchSafety Rating 7/10

Price Comparison

Compare vendors · per 10mg

24 vendors competing

VendorPrice$ / mgUpdated
Amino Club10/10$55.99$69.99−20% · code PEPTIDEPRICES$5.60May 14, 2026Buy →
Woosh Labs8/10$62.10$69.00−10% · code peptideprices$6.21Jun 24, 2026Buy →
Puratek Peptides9.5/10$65.66$72.95−10% · code PEPTIDEPRICES$6.57May 19, 2026Buy →
Evo Labs Research8/10$67.99$79.99−15% · code JACKR3CCC$6.80Jun 22, 2026Buy →
Midwest Peptide8.5/10$80.99$89.99−10% · code PEPTIDEPRICES$8.10Jun 18, 2026Buy →
Red River Peptides6/10$42.50$50.00−15% · code PEPTIDEPRICES$8.50May 19, 2026Buy →

Research details

Cagrilintide — research data

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose range2.4 mg SC weekly (Phase 3 target)source ↗
AdministrationSubcutaneous injection
Half-life~6–7 days
Safety7/10 · Not FDA-approved (Phase III)
NCAA D1Not listed

Overview

About Cagrilintide

Mechanism of action

Long-acting amylin receptor agonist; amylin is co-secreted with insulin; activates amylin receptors in the hypothalamus and brainstem; reduces food intake, slows gastric emptying, reduces body weight; complements GLP-1 mechanisms via separate pathways.

Safety profile

Nausea, vomiting, diarrhea, injection site reactions; generally well-tolerated; similar GI profile to GLP-1 class. Still in trials. · Phase III trials show good tolerability; GI side effects; injection site reactions

Storage

Stability & handling

❄️Lyophilized (powder)−20°Clong-term
💉Reconstituted2–8°Cwithin days
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Related pages

More on Cagrilintide

Stack & Compare

Frequently Researched Together

Research

Studies & key findings

  • Long-acting fatty-acid-acylated amylin analogue with a 7-day half-life; combined with semaglutide 2.4 mg (CagriSema), produced ~25% mean body weight reduction in REIMAGINE Phase 2/3 — approaching surgical outcomes.
  • Structural studies (2025) revealed cagrilintide engages amylin receptors 1 and 3 in distinct brainstem regions for satiety, complementing GLP-1 receptor engagement by semaglutide for additive weight loss.

10 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch